Simulations Plus, Inc. (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor.
Founded in 2017, Nurocor offers a cloud-based software platform designed to improve efficiency, reusability, governance, and automation for pharmaceutical companies through digitalization in the clinical development phase. Its solution significantly accelerates the typical clinical trial lifecycle, resulting in a reduction of the overall cost of the clinical development process.
The investment was made as part of Simulations Plus’ Corporate Development Initiative , launched in 2024 to support early-stage technology companies accelerating innovations within the pharmaceutical industry.
“We are pleased to support Nurocor in its mission to help clients leverage technology to bring drugs to market more rapidly,” said Shawn O’Connor , Chief Executive Officer of Simulations Plus. “Their vision aligns with our own, and we see tremendous potential for clients to deploy our complementary solutions in clinical trial design, protocol development, and site competency and compliance. We believe our investment in Nurocor will deliver considerable and measurable value to clients and ultimately get much-needed treatments to patients faster.”
“We are excited to make this strategic investment through our Corporate Development Initiative,” said Will Frederick , Chief Financial Officer of Simulations Plus. “This initiative is specifically designed to foster growth for early-stage companies, as well as identify potential partners and acquisition targets that complement our organic growth strategy and expand our total addressable market.”
In 2024, the clinical trial technology and services sector—which encompasses digital tools and services—was estimated at $25.7 billion. It is projected to grow at a compound annual growth rate (CAGR) of 15.5% from 2025 to 2030, driven by the increasing adoption of digital health technologies and the growing demand for more efficient patient recruitment.
“We are thrilled to have the support of Simulations Plus as we enter our next stage of growth,” said Alex Lazar, Chief Executive Officer of Nurocor. “The investment is a strong vote of confidence in our team and technology, and we look forward to partnering with them to help clients realize efficiencies through the optimization and automation of their clinical trials.”
